Deal With Gilead For Anti-CD123 Bispecific Offers Breath Of Fresh Air For MacroGenics

MacroGenics believes its next-gen anti-CD123 candidate MGD024 has a potentially favorable toxicity profile, as other bispecifics with the same target have floundered. But it lacks the cash to advance on its own.